A large, imaging-intensive, biomarker-driven market. Page scoped, not yet live. Public-facing content remains light until cleared evidence and named-sponsor consents allow the surface to say more than the market framing.
An outline of what this page will cover when published.
$5B+ annual neuro trials market. Imaging-intensive, biomarker-driven, with a structural CRO gap created by imaging-CRO consolidation. A market fact, not a Perspectum claim about Perspectum.
Specific named sponsors and named studies stay off this page until each is cleared by Regulatory Affairs and, where applicable, by the sponsor. Per Brand Review v2 Section 8.1, only the five cleared big-pharma names (Lilly, Boehringer Ingelheim, Roche, Takeda, Merck) can be mentioned publicly without further consent.
Scoped, not yet live. The page exists in IA so that the four-pillar pharma roadmap reads as four pillars; the public-facing content stays minimal until Perspectum has commercial activity it can name and verify.
Lighter than the other three pharma TA pages while the evidence stack stands up. Minimum two of five bands at launch, flagged on the quarterly content audit. Source: Brand Review v2 Section 8.3.
This page is currently in development. The outline above shows what it will cover, with content owners noted on each card.
Talk to our pharma services team. We'll come back with a brief outlining trial design implications and a confidential proposal within five working days.
